Related Experiment Video
Updated: Aug 9, 2025

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
Published on: December 11, 2017
Cardiac Damage and Quality of Life After Aortic Valve Replacement in the PARTNER Trials
Philippe Généreux1, David J Cohen2, Philippe Pibarot3
1Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey, USA.
Insights
Extravalvular cardiac damage significantly impacts health status in severe aortic stenosis patients undergoing aortic valve replacement (AVR). Higher damage levels correlate with poorer outcomes and less health status improvement post-AVR.
Area of Science:
- Cardiology
- Cardiac Surgery
- Medical Imaging
Background:
- Severe aortic stenosis poses risks, with extravalvular cardiac damage exacerbating adverse event rates.
- Aortic valve replacement (AVR) is a critical intervention for severe aortic stenosis.
Purpose of the Study:
- To investigate the association between the extent of cardiac damage and patient health status before and after AVR.
- To evaluate the impact of baseline cardiac damage on 1-year health status outcomes.
Main Methods:
- Pooled data from the PARTNER 2 and 3 trials (n=1,974) including surgical and transcatheter AVR.
- Echocardiographic assessment of cardiac damage staged 0-4 at baseline and 1 year.
- Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS) used to assess health status.
Main Results:
- Baseline cardiac damage correlated with lower KCCQ-OS scores at baseline and 1 year post-AVR (P < 0.0001).
- Increased cardiac damage stages were linked to higher rates of poor outcomes (death or significant KCCQ-OS decline) at 1 year (P < 0.0001).
- Each 1-stage increase in baseline damage raised the odds of a poor outcome by 24% (P=0.001).
Conclusions:
- Pre-procedural cardiac damage significantly influences health status outcomes, both cross-sectionally and following AVR.
- The degree of cardiac damage improvement post-AVR correlates with health status gains.
- These findings underscore the importance of assessing cardiac damage in AVR candidates.
Background:
The extent of extravalvular cardiac damage is associated with increased risk of adverse events among patients with severe aortic stenosis undergoing aortic valve replacement (AVR).
Objectives:
The goal was to describe the association of cardiac damage on health status before and after AVR.
Methods:
Patients from the PARTNER (Placement of Aortic Transcatheter Valves) 2 and 3 trials were pooled and classified by echocardiographic cardiac damage stage at baseline and 1 year as previously described (stage 0-4). We examined the association between baseline cardiac damage and 1-year health status (assessed by the Kansas City Cardiomyopathy Questionnaire Overall Score [KCCQ-OS]).
Results:
Among 1,974 patients (794 surgical AVR, 1,180 transcatheter AVR), the extent of cardiac damage at baseline was associated with lower KCCQ scores both at baseline and at 1 year after AVR (P < 0.0001) and with increased rates of a poor outcome (death, KCCQ-OS <60, or a decrease in KCCQ-OS of ≥10 points) at 1 year (stages 0-4: 10.6% vs 19.6% vs 29.0% vs 44.7% vs 39.8%; P < 0.0001). In a multivariable model, each 1-stage increase in baseline cardiac damage was associated with a 24% increase in the odds of a poor outcome (95% CI: 9%-41%; P = 0.001). Change in stage of cardiac damage at 1 year after AVR was associated with the extent of improvement in KCCQ-OS over the same period (mean change in 1-year KCCQ-OS: improvement of ≥1 stage +26.8 [95% CI: 24.2-29.4] vs no change +21.4 [95% CI: 20.0-22.7] vs deterioration of ≥1 stage +17.5 [95% CI: 15.4-19.5]; P < 0.0001).
Conclusions:
The extent of cardiac damage before AVR has an important impact on health status outcomes, both cross-sectionally and after AVR. (PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk (PII A), NCT01314313; The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B [PARTNERII B], NCT02184442; PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis [P3], NCT02675114).
More Related Videos
Related Concept Videos
Aortic Regurgitation III: Medical Management
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aortic Regurgitation IV: Nursing Management
Aortic Regurgitation I: Introduction
Mitral Stenosis IV: Nursing Management
Cardiomyopathy V: Interprofessional Care

